Navigation Links
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
Date:10/6/2008

An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.

In a study published in the Oct. 6 early online edition of the Proceedings of the National Academy of Sciences, a team led by Francis S. Collins, M.D., Ph.D., of the National Human Genome Research Institute (NHGRI), and Elizabeth G. Nabel, M.D., director of the National Heart, Lung and Blood Institute (NHLBI), describes its effort to use transgenic mice to identify and test potential therapies for children with Hutchinson-Gilford progeria syndrome.

There currently are no treatments for progeria, which is estimated to affect about one child in 4 million. At birth, children with progeria appear normal. But soon growth slows, and the children begin to show signs of accelerated aging, such as hair loss, wrinkled skin and loss of body fat. The most lethal damage, however, occurs within the children's major blood vessels. The children develop premature cardiovascular disease, which typically leads to death from heart attack or stroke at about the age of 13.

Building upon its past experiments in cells and mice, the NIH-led team examined the effects of an experimental cancer drug, tipifarnib, in a strain of mice genetically engineered to develop cardiovascular damage similar to that seen in progeria patients. Tipifarnib belongs to a class of drugs known as farnesyltransferase inhibitors (FTIs), which are being tested in people with myeloid leukemia, neurofibromatosis and other conditions. The team had previously found that FTI drugs could reverse structural abnormalities in skin cells taken from progeria patients and grown in the laboratory.

"This approach worked much better than we thought it would. Not only did this drug prevent these mi
'/>"/>

Contact: Geoff Spencer
spencerg@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
2. Novel anti-cancer mechanism found in long-lived rodents
3. Gene therapy anti-cancer research featured in Scientific American
4. Drug reverses mental retardation caused by genetic disorder
5. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
6. New discoveries from Harvard and Baylor get to the heart of cardiovascular disease
7. Gladstone and Izumi Bio in partnership in regenerative medicine and cardiovascular disease
8. New research shows no link between aromatase inhibitors and cardiovascular problems
9. Genetic variants of USF1 are associated with the increased risk for cardiovascular disease
10. Cell Therapy for Cardiovascular Diseases
11. Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Biologists have known for a long time that some ... well understood, particularly for plants. But it may be ... Australian National University and the U. S. National Evolutionary ... published 21 May in the journal Nature Communications ... faster-changing genomes. , Drawing from a database of global ...
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... cells in the blood often jump into action ... that can fight off illness. But repeated infections ... leading to the development of serious blood conditions ... led by biologists at the California Institute of ... the molecule microRNA-146a (miR-146a) acts as a critical ...
Breaking Biology News(10 mins):Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... issue of Sports Technology , published by ... the gap between able-bodied athletes and para-athletes, with ... first article, entitled "Biomechanics of double transtibial amputee ... al., compares the sprinting mechanics data of able-bodied ...
... patients with a particularly aggressive form of skin cancer ... from simply hearing that diagnosis, might amplify the progression ... that infers this also suggests that the use of ... of those tumors and therefore improve these patients, quality ...
... Entrust, Inc. (Nasdaq: ENTU ), a world leader in ... fiscal quarter and year ended December 31, 2008.Fourth-Quarter 2008, ... of $24.9 million, a decrease of 7% over Q4 2007; total ... million, an increase of 5%, adjusting for currency , ...
Cached Biology News:Stress may hasten the growth of melanoma tumors 2Stress may hasten the growth of melanoma tumors 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 2Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 3Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 4Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 5Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 6Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 7Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 8Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 9Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 10Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 11Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 12Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 13Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 14Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 15Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 16Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 17Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 18Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 19Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 20Entrust Announces Financial Results for Fourth-Quarter and Fiscal 2008 21
(Date:5/23/2013)... -- Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today announced that Jeffrey ... two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ) ... Annual Marcum LLP Microcap Conference on Thursday, May 30, ... City.  The presentation is scheduled to begin at 4:30 ...
(Date:5/23/2013)... 23, 2013 Pusan National University Yangsan ... biotherapeutics and contract research company focused on research ... announced today a publication reporting the induction of ... oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex ... in the May 15 th , 2013 issue ...
(Date:5/23/2013)... May 23, 2013 African ... tracing for people of African descent, today announced ... offering. For people of all races, myDNAmix determines ... five distinct populations: Indigenous Americas (Native American), East ... Subcontinent. , Originally launched in late ...
(Date:5/23/2013)... 2013 Bed bugs compromised Penn ... already confirmed it. Meanwhile, My Cleaning Products offered complimentary samples ... fight the pests without using harmful chemical elements. , ... 2013, the affected building was actually a dormitory , ... said made on May 13 and bed bug presence was ...
Breaking Biology Technology:Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... Harriet L. Robinson, Ph.D., Chief Scientific Officer at ... in the development of HIV/AIDS vaccines, announced the results ... step closer to a vaccine that protects against multiple ... by Dr. Robinson during a presentation in Seattle at ...
... local product advancements and a strong 2012 research pipeline ... growth, Pioneer President Paul E. Schickler told ... "Global trends like an expanding middle class ... demand for food and require constant innovation, global science ...
... March 7, 2012 Palatin Technologies, Inc. (NYSE Amex: ... the 24th Annual ROTH OC Growth Stock Conference on Tuesday, ... will be held at the Ritz Carlton Laguna Niguel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
Cached Biology Technology:GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 2GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 3GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI) 4DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 2DuPont Leader Overviews 2012 Seed Research Pipeline with Investors 3
Mycoplasma and virus tested...
... MagicMark and MagicMark XP Western Protein ... and convenient protein molecular weight estimation ... protein contains an IgG binding site, ... antibody-conjugate reagents used to detect your ...
... Immunogen: Synthetic peptide derived ... JAB1 (Jun activation domain-binding protein ... for the JAB1 protein. ... Jurkat cell lysates). Applications: ...
...
Biology Products: